Radiation exposure associated with more aggressive thyroid cancer, worse outcomes

April 20, 2009

Patients with thyroid cancer who have previously been exposed to radiation--for example, in the workplace, through environmental exposure or for treatment of acne or another condition--appear to have more aggressive disease and tend to have worse outcomes in the long term, according to a report in the April issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

"Thyroid cancer is one of the well-known malignant neoplasms [tumors] associated with radiation exposure," the authors write as background information in the article. "It often induces characteristic histologic changes in thyroid tissue, and it is a well-established risk factor for both benign and malignant thyroid tumors. This is supported by epidemiologic studies in atomic bomb survivors and in children living in contaminated areas around Chernobyl, Ukraine, after the 1986 nuclear reactor accident."

Raewyn M. Seaberg, M.D., Ph.D., and colleagues at Mount Sinai Hospital, Toronto, Ontario, Canada, studied 125 patients who had been exposed to radiation at least three years before surgical treatment for thyroid cancer. All the patients were treated at one academic teaching hospital between 1963 and 2007.

Most (56 percent) had a history of direct radiation exposure to the head and neck, usually for the treatment of acne or another benign condition. Six percent had direct radiation exposure to other parts of the body; 23 percent had occupational or diagnostic exposures, such as radiographic technicians, dental assistants or patients exposed to repeated imaging procedures; 11 percent had environmental exposures, such as those in Chernobyl; and 4 percent had received radioactive iodine treatment. The average age at first exposure to radiation was 19.4 years, and cancers were diagnosed an average of 28.7 years later.

Patients were followed for an average of 10.6 years. During this time, 16 percent experienced a recurrence of the disease in the thyroid and 9 percent had cancer that had metastasized (spread) to distant areas. At the last follow-up, 86 percent were alive and free of disease, 4 percent were alive with recurrent thyroid cancer, 4 percent were alive with distant metastases, 4 percent had died of the disease and 2 percent had died of unrelated causes.

These patients were compared with a group of 574 patients of similar ages and sex distribution who also were treated for thyroid cancer but were not exposed to radiation beforehand. The radiation-exposed group was more likely to undergo total or near-total thyroidectomy (removal of the thyroid, 83 percent vs. 38 percent), require additional surgery (23 percent vs. 2 percent), have stage IV disease (16 percent vs. 5 percent), have distant metastases (9 percent vs. 2 percent), have thyroid cancer at follow-up (8 percent vs. 3 percent) or have died of the disease (4 percent vs. 1.5 percent).

"Therefore, this study suggests that patients who have been exposed to radiation have more aggressive disease and worse clinical outcome than other patients with thyroid cancer and, therefore, may require more aggressive treatment," they conclude.
-end-
(Arch Otolaryngol Head Neck Surg. 2009;135[4]:355-359. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Dr. Freeman holds the Temmy Latner/Dynacure Chair in Head and Neck Oncology. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

The JAMA Network Journals

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.